Axa S.A. Acquires New Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AXA S.A. acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 38,543 shares of the specialty pharmaceutical company's stock, valued at approximately $4,747,000. AXA S.A. owned approximately 0.06% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. LSV Asset Management increased its position in shares of Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after acquiring an additional 37,108 shares during the period. Pacer Advisors Inc. raised its position in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares during the period. Capital World Investors increased its stake in shares of Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after buying an additional 104,195 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 4.8% in the fourth quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock valued at $195,506,000 after acquiring an additional 72,007 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the transaction, the chief executive officer now directly owns 439,307 shares of the company's stock, valued at approximately $51,113,369.45. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded down $0.60 during trading hours on Friday, reaching $97.81. 1,217,193 shares of the stock were exchanged, compared to its average volume of 833,461. The stock has a market cap of $6.03 billion, a P/E ratio of 13.78, a P/E/G ratio of 1.04 and a beta of 0.38. The firm's 50 day moving average is $118.96 and its 200 day moving average is $122.19. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 EPS. Analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JAZZ. Piper Sandler reissued an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday. StockNews.com lowered Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Barclays reaffirmed an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird dropped their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, Needham & Company LLC restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $182.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.